JNJ 40346527

Drug Profile

JNJ 40346527

Alternative Names: JNJ-244; JNJ-40346527; JNJ-527

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen Research & Development
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Small molecules
  • Mechanism of Action Macrophage colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hodgkin's disease; Inflammation; Rheumatoid arthritis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 24 May 2013 Johnson & Johnson plans a clinical trial for Crohn's disease (J&J Business Review 2013)
  • 01 Apr 2013 Janssen Research & Development completes a phase I trial in Hodgkin's disease (second-line therapy or greater) in France and Germany (NCT01572519)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top